Speakers
Rakesh Dixit
Chief Executive Officer & Founder
BioNavigen
Bill Mallet
Staff Scientist
Target Validation Bolt Bio
Day One
Tuesday December 7, 2021
2:00 pm | Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug
10:30 am | Immune-Stimulating Antibody Conjugates Targeting CEA & PD-L1 for Cancer Therapy
Earl Albone
Senior Director of Biochemistry & Bioanalytical Development
Eisai, Inc
Day Two
Wednesday December 8, 2021
2:30 pm | Session Reserved for Eisai
Elaine Hurt
Director, Bioscience
AstraZeneca
Greg Adams
Chief Scientific Officer
Elucida Oncology, Inc
Day Two
Wednesday December 8, 2021
10:30 am | Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors
Hans Peter Gerber
Chief Scientific Officer
3T Bioscionces
Day One
Tuesday December 7, 2021
2:00 pm | Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug
Day Two
Wednesday December 8, 2021
10:00 am | Identification of Novel pHLA Targets for Solid Tumor Targeting with ADCs
Jack Elands
Chief Executive Officer
Emergence Therapeutics
Jagath Reddy Junutula
Founder
Aarkus Therapeutics
Day One
Tuesday December 7, 2021
3:30 pm | Chair’s Closing Remarks
10:20 am | Chair’s Opening Remarks
Day Two
Wednesday December 8, 2021
3:00 pm | Chair’s Closing Remarks
10:00 am | Chair's Opening Remarks
John Lambert
Independent Consultant
Lenka Sadilkova
Director of Pharmacology
SOTIO
Day Two
Wednesday December 8, 2021
12:00 pm | SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors
Martha R. Neagu
Medical Director, Oncology Early Development
AbbVie
Day One
Tuesday December 7, 2021
12:00 pm | Targeting EGFR Through ADCs
Regina Reilly
Oncology Discovery, Biologics & Research Fellow
AbbVie
Day Two
Wednesday December 8, 2021
2:00 pm | Target Identification at the Intersection of Indication & Payload
Robert Lawrence
Senior Scientist
Seagen
Day One
Tuesday December 7, 2021
2:00 pm | Panel Discussion: Ensuring Your ADC Is Fit For Purpose; Matching the Target Selection to the Property of Your Warhead or Your Linker Drug
Day Two
Wednesday December 8, 2021
12:30 pm | Quantitative Proteomics Approaches for ADC Target Characterization
Seema Kantak
Vice President
Exelixis
Day One
Tuesday December 7, 2021
2:30 pm | Target Expression & Warhead: The Driving Forces of ADC Activity
Terry Rabbits
Molecular Immunologist
ICR
Day One
Tuesday December 7, 2021
12:30 pm | Targeting Leukaemias with Anti-CD7 Antibody & ADC
Tracy Kuo
Senior Director - Biology & Translational Science
Tallac Therapeutics
Day One
Tuesday December 7, 2021